[go: up one dir, main page]

MX2023009954A - Compuestos de aminopirimidina y métodos de uso de estos. - Google Patents

Compuestos de aminopirimidina y métodos de uso de estos.

Info

Publication number
MX2023009954A
MX2023009954A MX2023009954A MX2023009954A MX2023009954A MX 2023009954 A MX2023009954 A MX 2023009954A MX 2023009954 A MX2023009954 A MX 2023009954A MX 2023009954 A MX2023009954 A MX 2023009954A MX 2023009954 A MX2023009954 A MX 2023009954A
Authority
MX
Mexico
Prior art keywords
methods
compounds
sup
aminopyrimidine compounds
aminopyrimidine
Prior art date
Application number
MX2023009954A
Other languages
English (en)
Inventor
Robert L Hudkins
Daniel C Bensen
Original Assignee
Tyra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyra Biosciences Inc filed Critical Tyra Biosciences Inc
Publication of MX2023009954A publication Critical patent/MX2023009954A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos de aminopirimidina sustituidos de fórmula I: (ver formula I), y sales farmacéuticamente aceptables de estos, en donde Ar, R1 , y R2 tienen los significados descritos en la presente; composiciones farmacéuticas que incluyen tales compuestos, y métodos para usar tales compuestos.
MX2023009954A 2021-02-26 2022-02-25 Compuestos de aminopirimidina y métodos de uso de estos. MX2023009954A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163154409P 2021-02-26 2021-02-26
US202163216868P 2021-06-30 2021-06-30
US202263303284P 2022-01-26 2022-01-26
PCT/US2022/017873 WO2022182972A1 (en) 2021-02-26 2022-02-25 Aminopyrimidine compounds and methods of their use

Publications (1)

Publication Number Publication Date
MX2023009954A true MX2023009954A (es) 2023-11-09

Family

ID=80738915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009954A MX2023009954A (es) 2021-02-26 2022-02-25 Compuestos de aminopirimidina y métodos de uso de estos.

Country Status (11)

Country Link
US (1) US20240190849A1 (es)
EP (1) EP4297873A1 (es)
JP (1) JP2024509795A (es)
KR (1) KR20230154436A (es)
AU (1) AU2022226671B2 (es)
BR (1) BR112023016986A2 (es)
CA (1) CA3211124A1 (es)
IL (1) IL305178A (es)
MX (1) MX2023009954A (es)
TW (1) TW202246243A (es)
WO (1) WO2022182972A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN120417905A (zh) * 2022-10-18 2025-08-01 阿斯利康(瑞典)有限公司 用于将大分子递送至细胞的组合物和方法
WO2025117875A1 (en) 2023-11-29 2025-06-05 Tyra Biosciences, Inc. Compounds for treating solid tumors having activating fgfr2 gene alterations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP2009541318A (ja) * 2006-06-22 2009-11-26 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102243505B (zh) 2011-07-07 2013-08-14 矽力杰半导体技术(杭州)有限公司 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路
WO2013021950A1 (ja) 2011-08-05 2013-02-14 アステラス製薬株式会社 新規ｆｇｆｒ４変異体の検出法
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
US10323285B2 (en) 2013-09-09 2019-06-18 Nantomics, Llc Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods
AU2014362227B2 (en) 2013-12-11 2021-05-13 Accuragen Holdings Limited Compositions and methods for detecting rare sequence variants
JP6514645B2 (ja) 2013-12-27 2019-05-15 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
EP3102705A4 (en) 2014-02-04 2017-10-25 Mayo Foundation for Medical Education and Research Method of identifying tyrosine kinase receptor rearrangements in patients
KR20160138494A (ko) 2014-03-31 2016-12-05 데비오팜 인터네셔날 에스 에이 Fgfr 융합물
KR20170044172A (ko) 2014-08-28 2017-04-24 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법
JP2018027019A (ja) 2014-11-26 2018-02-22 国立研究開発法人国立がん研究センター 胆道がんにおける新規治療標的融合遺伝子
EP3699290A1 (en) 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
WO2016112302A1 (en) * 2015-01-09 2016-07-14 Metastat, Inc. Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor
CN105837576B (zh) * 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
RU2760359C2 (ru) * 2015-09-25 2021-11-24 Дизал (Цзянсу) Фармасьютикалз Ко., Лимитед Соединения и способы для ингибирования JAK
FI3571192T3 (fi) * 2017-01-17 2023-03-06 Astrazeneca Ab Jak1-selektiivisiä inhibiittoreita
WO2019242689A1 (zh) * 2018-06-22 2019-12-26 北京赛特明强医药科技有限公司 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US12350265B2 (en) * 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
US20230115945A1 (en) * 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds

Also Published As

Publication number Publication date
AU2022226671A9 (en) 2024-09-19
IL305178A (en) 2023-10-01
TW202246243A (zh) 2022-12-01
JP2024509795A (ja) 2024-03-05
BR112023016986A2 (pt) 2023-11-07
US20240190849A1 (en) 2024-06-13
KR20230154436A (ko) 2023-11-08
AU2022226671A1 (en) 2023-08-24
CA3211124A1 (en) 2022-09-01
EP4297873A1 (en) 2024-01-03
WO2022182972A1 (en) 2022-09-01
AU2022226671B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
CR20200503A (es) Inhibidores de cinasa dependientes de ciclina
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EP3693369A3 (en) Bromodomain inhibitors
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
MX2022015886A (es) Derivados de amidopirimidona.
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
MX2024013838A (es) Compuestos y usos de estos
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2023015139A (es) Inhibidores de mutacion de her2.
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
PH12021552513A1 (en) Pyrrole compounds
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2025002166A (es) Compuestos y metodos para modular her2
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
PH12021552953A1 (en) Tricyclic compounds
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.